# Abbott Laboratories

Type: Company

Source: GetYourBrief — https://getyourbrief.com/entity/abbott-laboratories
Canonical HTML page: https://getyourbrief.com/entity/abbott-laboratories

## Timeline

- **2026-09-01**: MiniMed scheduled to report fiscal Q1 2027 results — MiniMed Group will report its fiscal Q1 2027 results, the first earnings check after the MiniMed Flex U.S. launch.
- **2026-08-17**: MiniMed announces U.S. commercial shipping of MiniMed Flex with Abbott Instinct — MiniMed Group says its Flex automated insulin delivery system is now shipping in the U.S. integrated with Abbott's Instinct 15-day continuous glucose sensor.
- **2026-06-04**: Judge Rules Lawsuit Can Proceed — US District Judge Paul Engelmayer issues a 75-page decision allowing the class-action lawsuit against Abbott Laboratories over PediaSure marketing claims to move forward to trial.

## Recent coverage (14 stories, network-wide)

### Abbott's 42% Diagnostics Surge vs Thermo Fisher's Recovery: Which Wins?
2026-08-24 02:36:34 · Sector: health · Sentiment: Neutral · Impact: 5/10 · Sources: 2

For health system executives, clinical lab directors, and healthcare investors, this comparison is a real-world barometer of whether diversified diagnostic platforms or life sciences recovery will shape vendor and research spending. Abbott's 42% diagnostics jump to $3.09B, driven by Cologuard and Exact Sciences, points to durable non-invasive screening demand. Thermo Fisher's improving pharma and biotech activity signals a potential rebound in research tool budgets.
Full story: https://gethealthbrief.com/story/abbott-thermo-fisher-health-diagnostics-vs-recovery

### Abbott-MiniMed Flex Diabetes System Ships with 80% Time in Range
2026-08-22 07:04:32 · Sector: health · Sentiment: Positive · Impact: 6/10 · Sources: 2

The Abbott-MiniMed Flex integration is now shipping in the U.S., pairing Abbott's 15-day Instinct sensor with MiniMed's smallest app-controlled insulin pump. Clinicians and health systems gain a real-world data point of 80% Time in Range, while payers will weigh the combined system's value against entrenched CGM and AID competitors.
Full story: https://gethealthbrief.com/story/abbott-minimed-flex-instinct-80-tir

### CareDx +35% on Medicare Win; Atai +33% on $3.8B Lilly Deal
2026-08-05 07:28:34 · Sector: bio · Sentiment: Positive · Impact: 6/10 · Sources: 2

CareDx surged 35% after Medicare finalized coverage for transplant rejection tests, unlocking a major revenue opportunity. AtaiBeckley soared 33% following Eli Lilly's $3.8B acquisition, while Abbott raised its outlook and Apollomics extended its weekly rally to over 60% on its cancer drug candidate.
Full story: https://getbiobrief.com/story/caredx-atai-abbott-biotech-gainers-2026

### 75-Page Decision: Abbott Must Defend PediaSure 'Grow & Gain' Marketing in Court
2026-08-04 21:28:42 · Sector: legal · Sentiment: Neutral · Impact: 5/10 · Sources: 2

A New York federal judge's detailed opinion allowing a deceptive-labeling suit to proceed could set a precedent for consumer class actions against health-related product claims.
Full story: https://getlegalbrief.com/story/abbott-pediasure-class-action-lawsuit-legal

### Abbott Beats Q2 with $12.59B Revenue, Analysts Raise PT to $134; UNH Also Surges
2026-07-25 20:28:16 · Sector: bio · Sentiment: Positive · Impact: 7/10 · Sources: 1

Abbott Laboratories reported Q2 revenue of $12.59 billion (+13% YoY), beating estimates and raising its full-year EPS guidance. Analysts hiked price targets in response, with BTIG going to $134, reflecting confidence in its diversified healthcare portfolio and pipeline. UnitedHealth also delivered a massive EPS beat, but Abbott’s medtech and diagnostics momentum carries particular relevance for the biopharma sector.
Full story: https://getbiobrief.com/story/abbott-unh-q2-2026-beat-analyst-target-hikes-bio

### AI Startup Valuations Face Chilling Test as Nasdaq Tanks 1.5%
2026-07-20 04:09:45 · Sector: startups · Sentiment: Negative · Impact: 6/10 · Sources: 6

The July 16 Nasdaq decline of 1.5%, driven by an AI chip rout, is sending ripples through the venture capital ecosystem. With public comps re-rating rapidly, late-stage AI startups may find their lofty valuations under severe pressure, potentially stalling fundraising and IPOs.
Full story: https://getstartupbrief.com/story/ai-startup-valuations-nasdaq-15-drop

### Nasdaq Sinks 1.5% as AI Chip Crash Tests Cloud Giants' $200B Infrastructure Bets
2026-07-20 04:09:34 · Sector: saas · Sentiment: Negative · Impact: 6/10 · Sources: 6

The Nasdaq's 1.5% drop on July 16, driven by AI chipmakers like Nvidia (-2.4%) and memory stocks, raises urgent questions about the ROI of massive cloud infrastructure investments. With broader markets resilient, the sell-off signals a potential repricing of AI-driven growth assumptions that underpin SaaS and cloud valuations.
Full story: https://getsaasbrief.com/story/nasdaq-ai-chip-crash-cloud-infrastructure

### S&P 500 Dips 0.5% as AI Rout Can't Hide 75% Stock Gains
2026-07-20 04:09:19 · Sector: finance · Sentiment: Negative · Impact: 6/10 · Sources: 6

While the S&P 500 slipped 0.5% on July 16, the decline was entirely attributable to a handful of overvalued AI chip stocks. Nearly three-quarters of index members rose, with healthcare and freight sectors rallying. The sell-off reveals a powerful rotation under the surface that could reshape portfolio allocations.
Full story: https://getfinancebrief.com/story/sp500-ai-rout-broad-market-strength

### AI Chip Stocks Crash: Nvidia -2.4%, Sandisk -12.6% as Overvaluation Bites
2026-07-20 04:09:07 · Sector: ai · Sentiment: Negative · Impact: 6/10 · Sources: 6

The AI sector suffered a severe reality check on July 16, with Nvidia dropping 2.4%, Sandisk plummeting 12.6%, and other chipmakers sliding sharply. The sell-off, driven by fears of overvaluation and unsustainable demand, could mark a turning point in how markets price the AI boom—and how AI companies plan their hardware roadmaps.
Full story: https://getaibrief.com/story/ai-chip-stocks-overvaluation-bites

### Abbott lifts 2026 EPS forecast to $5.45-$5.60 on 9% device growth
2026-07-17 03:46:04 · Sector: health · Sentiment: Positive · Impact: 6/10 · Sources: 2

Abbott raises its 2026 profit outlook as medical device sales jump 9% to $5.85B and diabetes care climbs 11%, proving the resilience of advanced cardiac and CGM technologies. The beat and guidance hike signal that hospitals continue to prioritize high-acuity procedures even under volume pressure.
Full story: https://gethealthbrief.com/story/abbott-2026-profit-forecast-device-growth

### Cancer diagnostics push Abbott's 2026 EPS guidance to $5.45-$5.60
2026-07-17 03:45:55 · Sector: bio · Sentiment: Positive · Impact: 6/10 · Sources: 2

Abbott’s newly acquired oncology diagnostics from Exact Sciences—Cologuard and Oncotype DX—are offsetting COVID testing declines and powering a Q2 earnings beat. The company lifted its full-year 2026 adjusted EPS target, highlighting the value of high-margin, recurring precision testing businesses.
Full story: https://getbiobrief.com/story/abbott-cancer-diagnostics-2026-eps-forecast

### AI Stock Selloff Deepens: Nasdaq Falls 1.5% as Nvidia Drops 2.4%
2026-07-16 20:39:00 · Sector: ai · Sentiment: Neutral · Impact: 6/10 · Sources: 8

AI chip stocks tumbled again on July 16, 2026, with Nvidia falling 2.4% and Micron down 5.6%, dragging the tech-heavy Nasdaq to a 1.5% loss. The selloff extends a weeks-long correction fueled by valuation worries and questions over the sustainability of AI hardware demand.
Full story: https://getaibrief.com/story/ai-stocks-selloff-nasdaq-falls-1-5

### Nasdaq Sinks 1.5% as AI Rout Spreads; 75% of S&P 500 Stocks Still Rise
2026-07-16 20:36:23 · Sector: finance · Sentiment: Neutral · Impact: 6/10 · Sources: 8

A concentrated sell-off in AI-driven chipmakers slammed the Nasdaq on July 16, even as strong earnings from healthcare and freight companies boosted over 75% of S&P 500 stocks. The divergence underscores a market rotation that threatens index-level returns while creating pockets of opportunity in undervalued sectors. Rising oil prices add a macro risk that could further pressure tech valuations.
Full story: https://getfinancebrief.com/story/nasdaq-sinks-ai-rout-broad-market-gains-2026

### Scaling Diabetes Care: The 2026 Outlook for Glucometer Manufacturing
2026-03-23 09:02:25 · Sector: health · Sentiment: Neutral · Impact: 5/10 · Sources: 2

As global diabetes prevalence reaches record highs, the shift toward localized medical device production is driving a surge in glucometer manufacturing plant investments for 2026. This briefing analyzes the cost structures, regulatory hurdles, and technological requirements for establishing high-volume diagnostic production facilities.
Full story: https://gethealthbrief.com/story/glucometer-manufacturing-plant-setup-2026-cost-analysis

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getyourbrief.com/guides/methodology for the full editorial methodology.